Clinical trials: Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure With Preserved Ejection Fraction, Venous Disease
HFpEF and Symptomatic Obstructive Iliofemoral Venous Disease Study
To ascertain the potential symptom improvement assessed by Cardiopulmonary Exercise Testing (CPET) in subjects with heart failure with preserved ejection fraction (HFpEF) and nonthrombotic iliofemoral venous lesions and/or…
- Trial name
- PERSUADE (NCT04964817)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Prairie Education and Research Cooperative
Heart Failure With Preserved Ejection Fraction
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).
- Trial name
- EQUINOX (NCT07795814)
- Testing
- EDG-15400 25 mg, EDG-15400 50 mg
- Where
- 28 sites in United States
- Volunteers
- 90 people
- Sponsor
- Edgewise Therapeutics, Inc.
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
- Trial name
- AMBER-HFpEF (NCT06793371)
- Testing
- CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
- Where
- 26 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cytokinetics
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy
This will be a two-arm investigator-initiated randomized controlled study of patients with nHCM and LV ejection fraction ≥50% and NYHA II-III symptoms, normal intrinsic conduction system and pre-existing suitable dual-chamber…
- Trial name
- PACE-nHCM (NCT06775886)
- Testing
- myPACE+ algorithm
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)
- Trial name
- NCT07093528
- Testing
- Cardiovascular Magnetic Resonance (CMR)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic